Active PresentFuture Positive

Investor PresentationAugust 2013

Disclaimer

This presentation and the accompanying slides (the Presentation), which has been prepared by Strides Arcolab Limited (the "Company"), has been prepared forinformation purposes only and is not, and is not intended to be, an offer, or solicitation of offer, or invitation or recommendation to buy or sell any securities of theCompany, and shall not constitute an offer, solicitation or invitation or recommendation to buy or sell in any jurisdiction in which such offer, solicitation or invitation orrecommendation is unlawful. No part, or all, of this Presentation shall form the basis of, or be relied on in connection with, any contract or investment decision in relationto any securities of the Company.

Nothing in the foregoing shall constitute and/or deem to constitute an offer or an invitation to an offer, to be made to the Indian public or any section thereof throughthis document, and this document and its contents should not be construed to be a prospectus in India. This document has not been and will not be reviewed orapproved by any statutory or regulatory authority in India or by any stock exchange in India.

This Presentation is strictly confidential and may not be copied, published, distributed or transmitted to any person, in whole or in part, by any medium or in any form forany purpose. The information in this Presentation is being provided by the Company and is subject to change without notice. This Presentation has been prepared by theCompany based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever,and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be allinclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation isexpressly excluded.

This Presentation contains statements about future events and expectations that are forward-looking statements. These statements typically contain words such as"expects" and "anticipates" and words of similar import. Any statement in this Presentation that is not a statement of historical fact is a forward-looking statement thatinvolves known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from anyfuture results, performance or achievements expressed or implied by such forward-looking statements. None of the future projections, expectations, estimates orprospects in this Presentation should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptionson which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in thePresentation. The Company assumes no obligations to update the forward-looking statements contained herein to reflect actual results, changes in assumptions orchanges in factors affecting these statements.

You acknowledge that you will be solely responsible for your own assessment of the market, the market position, the business and financial condition of the Company andthat you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

This Presentation speaks as of 30th June 2013. Neither the delivery of this Presentation nor any further discussions of the Company with any of the recipients shall, underany circumstances, create any implication that there has been no change in the affairs of the Company since that date.

This Presentation is not being made and will not be made directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality of interstate orforeign commerce of, or any facilities of a national securities exchange of, the United States. This includes, but is not limited to, facsimile transmission, electronic mail,telex, telephone and the Internet. Neither this Presentation nor any copy of this Presentation is being, and must not be taken or transmitted into the United States ordistributed, directly or indirectly, in the United States. The information presented herein is not an offer for sale within the United States of any equity shares or othersecurities of the Company. No offering of the Companys securities is being made nor will any offering of the Company's securities be registered under the U.S. SecuritiesAct of 1933, as amended (the Securities Act). Accordingly, unless an exemption from registration under the Securities Act is available, the Companys securities may notbe offered, sold, resold, delivered or distributed, directly or indirectly, into the United States.

The distribution of this Presentation in certain jurisdictions may be restricted by law and persons into whose possession this Presentation comes should inform themselvesabout and observe any such restrictions

Local market value (LMV) is provided as a reference for assessing the overall market value for a particular type of pharmaceutical product. It should not be consideredas an indicator of Strides sales of any its pharmaceutical products or the expected performance of such products in the future. Extrapolation of performance for aparticular product from LMVs for such types of products, is an inappropriate use of LMV data. There can be no assurance that our approved pharmaceutical products willbe successfully commercialized, or that our current filings will be approved

Introduction

169 172 222

326

427

FY08 FY09 FY10 FY11 FY12

Company overview

A leading Indian Pharmaceutical company operating in two major segments:

Specialties and Pharma

Offers wide range of products covering Orals, Semi Solids and Specialty

injectables including Beta-lactams, Cephalosporins, Oncolytics and Penems

Has one of the largest Lyophilzation (freeze drying) capacities in the world

Amongst the leading manufacturers of Soft Gelatin capsules in the world

Partnerships with leading global players like Pfizer, GlaxoSmithKline, Aspen,

Novartis, Sandoz, and Teva

Overview

Filings & approvals track record (ANDA)Geographical presence: 14 manufacturing plants+

marketing operations in 75 countries

Amongst highest steriles approvals in the industry

Revenue growth (USD mn)

1. Campos, Brazil2. Lagos, Nigeria3. Bangalore, Hosur & Mumbai, India4. Milan, Italy5. Warsaw, Poland

Plant locations

Marketing presence

5 Yr CAGR 26%

259* filings

110* approvals

4

2012 Revenues by Geography*

* Excludes Divested Australasia Business *includes purchased and divested ANDAs

INR/USD rate = 53.59

Africa,

10% Austral

asia ,

11%

North

America

, 32%Europe,

13%

South

America,

15%

ROW,

8%

ATM,

12%

* Excludes divested Ascent Australia operations

1

27

12

33

46

30 31

74

51

815

9

2227 25

3

2005 2006 2007 2008 2009 2010 2011 2012 2013

Filings Approvals

Business overview and structure

Specialties business (steriles)

Pharma and Branded Generics business (non-steriles)

2012 Revenue 2012 EBITDA 2012 Revenue 2012 EBITDA

Founded in 1990, Headquartered in Bangalore, India

2012 revenue of USD 436Mn and EBITDA of USD 106Mn

Listed on the Indian stock market since 2000

Restructured business into Pharma and Specialties in 2009

Legacy business of Strides established in 1990

Develops and manufactures immunosuppresants and soft gelatincapsules for regulated markets and antiretrovirals, anti-tuberculosis and anti-malaria drugs for programmes funded bydonor agencies such as PEPFAR and Global Fund

Commercial platform for the sale of branded and commoditygenerics, OTC and cosmeceuticals across Australia, Southeast Asia,Africa and India

Five global manufacturing plants in India, Italy and Nigeria,including one of the largest capacities in soft gelatin capsules withapprovals from the US FDA and other key regulatory authorities

Rebranded in 2010 as Agila to reinforce Strides focus onemerging as a sterile-driven pharmaceutical company

Develops and manufactures sterile injectable generics andspecialties for its B2B and B2C business across therapeutic areas,including anti-infectives, oncology, antibiotics, steroids,cephalosporins, CNS, gastro intestinal, ophthalmics and peptides

Nine global manufacturing facilities in India, Brazil and Poland,including one of the largest steriles capacity in India and amongstthe largest lyophilisation capacities globally

Entered into a definitive agreement with Mylan for sale of itsspecialty subsidiary at an aggregate sum of USD 1.6bn in cash &potential consideration of upto USD 250Mn

5

42%USD 181Mn

19%USD 20Mn

58%USD255Mn

81%USD 86Mn

3352

80 8699

142162

202

248

329

481

436

1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012*

Combined revenues

Strides history and achievements

1994-2003 2008 onwards2004-2008

We continue to focus on pursuing Niche Value. With strong capabilities and commitment, we strive to deliver a cost-efficient operating model aligning consistent innovation and affordable medical care

Specialised manufacturing

Commenced manufacturing of steriles, soft gelatin capsules and anti-retroviral, tuberculosis and malaria drugs

Bolt-on acquisitions of manufacturing capacity

Regulated markets

Restructured into Pharma and Specialties with increased focus on Steriles business

Commercial partnerships with global pharma for regulated and emerging markets

Front ending in select geographies of North America, EU, Brazil, India & Asia

Monetised significant value creation and strengthened Balance sheet by sale of Australasia business to Watson

Front-end acquisitions and R&D pipeline

Acquisition and integration of front-end platforms in Southeast Asia (DHA), Australia (Ascent) and India (Grandix)

Acquisition of manufacturing facilities in Poland and Italy

Significant investment in building R&D pipeline for regulated markets (Pharma and Steriles)

(breakdown only available after 2007)Pharma

6

USD Mn

Founded in 1990 as a finished dosage formulation company focused on Africa

Specialties

* Divested Ascent Australasia operation to Watson in Jan 12 for AUD 375Mn

Significant investments completed in

manufacturing facilities

Significant investments completed in

specialties space

Recently FDA approved facilities will

accelerate the developed markets strategy

Focus on R&D resulting in industry leading

formulation expertise

Proven R&D capabilities for developed

markets

Employs around 350 scientists in its R&D

department, delivering average 35 ANDAs

annually

Partnership with Big Pharma

Partnerships with pharmaceutical majors

such as Pfizer, GSK, Novartis, Teva &

Aspen in US, Europe, Australia, LATAM,

and South Africa

Partnerships with Pfizer and GSK validates

Strides niche capabilities in sterile

injectables and pharmaceuticals portfolio

Targeting products with significant demand

Increasingly targets products that are (i) in

short supply (ii) near term patent expiries

(iii) difficult to manufacture segments

Moving towards larger sized molecules

Solid track record of regulatory compliance

Successful inspections by USFDA/EMEA/PIC

over the last few years.

Continue to maintain strong track record in

all Regulatory inspections.

Integrated capabilities spanning entire

product development cycle

Full services provider from identifying

business opportunities to product approval

and commercialization

Diversified portfolio across Specialties and

Pharma offers stability

Offers wide range of products covering

Orals, Semi Solids and Specialty injectables

including Beta-lactams, Cephalosporins,

Oncolytics and Penems

Broad product portfolio is critical for getting

GPO contracts in the US (Strides has a

contract for sterile injectables with Premier)

Solid track record of filings and approvals

259 ANDA filings (213 in steriles) and 110

Approvals (83 in steriles)

Branded generics product registrations:

300+ in Africa

1 2 3

6 5

4

7

8

Strides Key differentiators

7

Specialties Business

12

3

4

14

17

19

19

27

30

30

34

42

73

Sanofi

Watson

B Braun

Amgen

ACS Dobfar

Teva

Bedford

Mylan

Luitpold

Fresenius

Hikma

Hospira

Sandoz

Strides

Steriles - Snapshot

One of the most competitive steriles franchise

globally with 9 manufacturing facilities

Key strengths

One of the largest lyophilization (freeze drying)

capacities in the world

Full services player with a well diversified portfolio

Track record of filing average 40 ANDAs annually

in the last three years

Significant investment in manufacturing facilities

completed

Long term customer contracts and joint ventures

to provide stable revenue stream

High Potency Drugs (Oncology,

Peptides and Controlled

Substances)

Antibiotics

Penems & Penicillins

Cephalosporins

Suspension injections

Oncology

Minibags

Ophthalmics and Peptides to

be new domains

Product categories Wide range

Packaging formats All major types

Vials Liquid & Dry Powder

Pre filled syringes (PFS)

Ampoules

Market leading ability to package

in lyophilized form

Focus on pre filled syringes

and lyophilized formats

FDA injectables ANDA approvals by company 2008 to July2012

Note: * Includes product approvals with JV partners & ANDAs sold to Pfizer in Dec 2010

Source: Approval data sourced from US FDA9

Strategy focused on capturing higher value business and sustainable growth

Initial phase (2006 2008)Phase-I

[2005-2007]Phase-II

[2008-2010]Current Phase [2011 onwards]

PRODUCT FILINGS

MFG.CAPABILITIES

STRATEGY

SegmentNos of Filings

LMV$bn

Avg LMV$mn

Steriles 25 0.3 12

Oncology - - -

Pens & Penems 1 0.2 221

Ophthalmics - - -

Total 26 0.5

Building Global manufacturing

capabilities for Steriles , Cephalosporin's

& Beta lactams

Focus on Niche small value opportunistic

products with distribution of products

through JV model

SegmentNos of Filings

LMV$bn

Avg. LMV$mn

Steriles 46 2.2 47

Oncology 31 2.0 65

Pens & Penems 8 0.3 38

Ophthalmics - - -

Total 85 4.5

Consolidation and expansion of

Global manufacturing capabilities for

Steriles Injectables and Oncology

Focus on large value Niche Sterile and

Oncology products

Partnering with Big Pharmas Pfizer,

Teva etc with profit sharing

arrangement

10

SegmentNos of Filings

LMV$bn

Avg. LMV$mn

Steriles 79 9.3 118

Oncology 8 1.3 163

Pens & Penems

2 0.04 20

Ophthalmics 13 0.9 69

Total 102 11.5

High value creation domains

Biosimilars

Devices and delivery systems

Para IV & 505b(2)

To emerge as a first wave player for

most products going off-patent

Strengthening partnership for new

products/partners & new

Geographies

Building front ending business in

select geographies of USA, UK,

Canada, Asia, Turkey, Indonesia,

India, Nordic and Brazil

Continuing Licensing opportunities

in selected domains

10 11

103

58

181

232

58

205

422

Lyo (Incl-Onco) Liquid Vials Other Steriles

C

a

p

a

c

i

t

y

i

n

m

i

l

l

i

o

n

u

n

i

t

s

FDA approved capacity Year 2010 Current FDA approved capacity Total Capacity

5.8X 16.5X 2.3XCapacity expansion

Plant Year Approval Status

Sterile Product Division I

2007, 2009, 2011

Approved

Penicillin, Bangalore 2008 Approved

Cephalosporin 2009 Approved

Sterile Product Division -II 2011 Approved

Oncology 2011 Approved

Penems, Brazil 2012 Approved

Sterile Product Division -Hosur

2011 Approved

Poland 2012 Approved

USFDA Inspection Status

Well positioned in the industry where regulatory challenges are high

Significant FDA Approved capacitiesInvestments towards additional 561m sterile units capacity completed

Lyo (Non-Onco) Liquid Vials Other Steriles

11

197

2242

21 30

67

50

20

40

60

80

2006 2007 2008 2009 2010 2011 2012 H1'2013

12

Well Positioned For Regulated Markets Opportunity

Increasing focus on high value products

NUMBER OF ANDA FILINGS (LMV - $16.5 Bn) NUMBER OF ANDA APPROVALS (LMV- $3.5 Bn)

CUMULATIVE LMV OF ANDA APPROVALS (US$ BN)

Oncology - - 3 20 7 7 1 -

Steriles 19 7 19 22 14 23 67 5

Patented - - 3 3 3 5 19 4

Matured 19 7 19 39 18 25 49 1

Oncology - - - - - 12 15 -

Steriles - 1 13 5 16 13 6 2

Patented - - - - 1 1 - 1

Matured - 1 13 5 15 24 21 1

Oncology 1.9 2.1 2.1

Steriles 0.0 0.2 0.3 0.7 0.8 0.9 1.4

Patented - - - - 0.07 0.1 0.1 0.6

Matured 0.0 0.23 0.26 0.59 2.6 2.9 2.9

Filings Approvals

Steriles Oncology Steriles Oncology

Europe 42 41 22 21

ANZ 29 16 23 13

South Africa 71 17 33 1

Canada 24 22 16 13

Africa 195 22 144 20

Korea 1 24 - 19

Latin America 215 1 156 1

ROW 201 198 115 62

Total 778 341 509 150

Number of filings & Approvals in other Established and Emerging markets

1 135 16

25

212

0

5

10

15

20

25

30

2006 2007 2008 2009 2010 2011 2012 H1'2013

213* 83*

0.0 0.00.2 0.3

0.7

2.73.0

3.5

2006 2007 2008 2009 2010 2011 2012 H1'2013

Note: LMV (Local Market value): sales in US$ of equivalent products already being sold in the market, whether patented or generic.LMV is not an indicator of Strides expected sales; 12

On Thursday, 28 February 2013, Strides Arcolab announced that it has entered into a definitive agreement for

the sale of its specialties subsidiary, Agila Specialties Private Limited, and simultaneously its overseas specialties

subsidiary Agila Specialties Asia Pte. Limited, Singapore, has entered into a definitive agreement for the sale of

its subsidiaries, to Mylan Inc.

Aggregate sum of US$1,600 million in cash and potential additional consideration of up to US$250 million subject

to the satisfaction of certain conditions by Strides

At the base consideration, the transaction values Agila at 18.7x total EBITDA for the year ended 31

December, 2012

The transactions have been independently approved by the respective Board of Directors of Strides, its overseas

subsidiary and Mylan Inc.

The companies being divested recorded, in the aggregate, revenue of $255 million and EBITDA of $86 million for

the year ended 31 December, 2012

Closing of the transactions are conditioned upon Foreign Investment Promotion Board approval, customary anti-

trust approvals and other closing conditions. The transactions are not subject to financing conditions

The transactions do not include Agila Biotech

Pharma and Biotech business to be future growth areas for Strides

13

Value Creation - Sale of Agila Specialties division for an aggregate cash sum of US$1,600 Mn and potential additional consideration of up to US$250 Mn

Building knowledge base1996-2000

Opened first sterile facility

Focus on contract manufacturing

Investment in infrastructure

2001-2007

Defocused contract manufacturing

Decision to target regulated markets

Investment in R&D

Joint ventures

Accelerated filings and approvals2008-2011

Large value niche sterile and oncology products

Market-leading track record of filings and approvals

US FDA facility approvals

Big Pharma partnerships

Growth and profitability2012-onwards

Stable cash flows

Amongst the largest generic injectables pipelines

Best-in-class manufacturing, R&D and operations infrastructure

Strides Arcolab Limited (As at 27 February, 2013) Agila Specialties

Enterprise Value Consideration(1)

US$1,329

million

US$1,600

million

Creation of a Global Leader in Generic Injectables

Value Crystallisation

Source: CapIQ. ( 1) Excludes potential additional consideration of up to US$250 million.

14

Crystallising Significant Value Created at Agila

Following successful closing of the transaction, Strides Arcolab proposes to utilise proceeds towards

inter alia:

Retiring debt

Pre-tax distribution of approximately US$700 million to US$800 million to shareholders

Costs related to the satisfaction of contingent conditions

15

Proposed Use of Proceeds Post Closing

Pharma Business

Segments Overview and Key Growth Drivers

Leading generics platform focused on soft gelatin and immunosuppressants for theUS and European markets

Strong R&D capabilities with US FDA approved manufacturing infrastructure

Exhaustive pipeline focused on products with high entry barriers to drive growth

Pharma Generics

Emerging as a regional player in Southern India in niche branded pharmaceutical products

Portfolio of recognised brands in fast growing therapeutic segments

India Brands

Leading sales and marketing platform for branded generic pharmaceuticals and over-the-counter medicines across Central and Sub-Saharan Africa

Growth driven by launch of new products, expansion into new markets, and establishing local manufacturing

Africa Business

Agila Biotech marks the foray of Strides Arcolab into the biologics space

Planned investments for setting up a next-generation biologics facility in Johor, Malaysia , and to build a 15,000 sq. ft. state-of-the-art R&D facility in Bangalore

Agila Biotech

17

Strides Arcolab The Road Ahead for Pharma Division

18

18

Market Overview

Biologics* market expected to grow at a CAGR of 8%-10% during 2010 to 2025, against 4%-

6% for total pharmaceutical market

Biologics worth $ 59 Billion to lose patent protection by 2015

Biologics market expected to touch $227 billion by 2015 against $126 billion in 2009

Biosimilars# market expected to touch $13 billion by 2015

6 Biosimilars already approved and commercialized in EU

Agila Foray into

Biosim DomainAcquired 100% controlling stake in Inbiopro-a biotechnology focused company

Competitive

Advantage

Immediate access to a pipeline of 8 products, estimated to have global sales of US$ 28 billion,

with commercialization expected to begin in 2014

The products include 5 monoclonal antibodies which have use in cancer treatment further

strengthening Strides oncology products basket

Facilities access to high expression mammalian and microbial platform-based capabilities

High yielding cell lines in-licensed and improved upon

Definite advantage in the biologics industry, which is characterized by specialized expertise in

recombinant DNA technology and manufacturing process development with stringent and well

defined regulatory guidelines ,resulting in long gestation periods for product development

Manufacturing Facility

Executed agreement with Malaysian Bio-Xcell for establishment of customized facility to

manufacture Biopharmaceuticals and sterile Injectables in the Bio-XCell ecosystem in Johor,

Malaysia.

Facility will be built by Bio-XCell to the design requirements of Strides and will be leased out to

Strides on a long-term basis with lease rentals applicable from the date of commercialization

Agila BiotechBiosimilars Unfolding Opportunities

Agila Biotech marks the companys foray into the biologics space

Biologics represent the fastest growing market segment in Pharma accounting for six out of top ten

selling global drugs, with patents on first generation biologics expiring by 2020

Planned investments:

Next-generation biologics facility in Johor, Malaysia an advanced end-to-end multi-product

facility for the production of recombinant therapeutic proteins and monoclonal antibodies

(mAbs) from drug substance to drug product in vials, pre-filled syringes and lyophilised

products. Expected to come on-stream by end-2014, with significant capacity already

advance booked for partner operations

R&D facility in Bangalore capable of handling high-end research activities, catering to an

internal pipeline as well as partnering activities

Developing an internal pipeline of biosimilars, utilising the latest bacterial and mammalian

expression systems

19

Agila BiotechFuture Focus Area and Growth Drivers

Globally

competitive

Amongst the leading manufacturers of soft gelatin capsules in the world

Supplies oral products to regulated markets

Product

development

capability

Develops and manufactures different orals presentation forms and therapeutic categories

Softgel caps, tablets & capsules and semi solids

Strength in Immunosuppressants (2 Approved ANDA commercialized)

Among the first generic companies to get FDA Approval for Vancomycin Capsule ( LMV $300Mn)

47 ANDA (24 PEPFAR) filings till date of which 26 (19 PEPFAR) have already been approved

Stable revenue

stream

Orals plants can support growth with limited Capex requirements going forward

Large number of product filings completed

Long term customer contracts to provide stable revenue stream

Intellectual property led manufacturing partnership in USA, UK, Australia, New Zealand and South Africa

Manufacturing

overview

One of largest softgel capacities in the world with five dedicated lines in Orals Drug facility in Bangalore, India

Facility approved by major regulatory authorities such as USFDA, MHRA, MCC, TGA and ANVISA

EU approved semi solids facility in Milan, Italy

Soft gels Global disease initiative (AIDS/TB/Malaria)

Manufacturing

Pharma Business

20

Pharma Generics

Africa India

Description

Leading player manufacturing and marketing

volume driven generics and margins driven

branded products

Emerging as a niche player in branded

pharmaceutical products

Manufacturing2 dedicated facilities: 1 in Lagos, Nigeria and

1 in India

Orals plant in Bangalore also used for

manufacturing branded generics

FootprintWest Africa, French Africa & other parts of

Africa

Grandix has presence in 5 states in South

India

Products

Branded generics, Commodity generics and

OTC products marketed through own sales

team in partnership with local distributors

French Africa business is front ended

comprising ethically promoted and OTC

products

Grandix covers therapeutic areas of

diabetes, cardiovascular diseases,

neurology and female healthcare

Sales USD 27Mn USD 12Mn

Ownership 80% stake (20% invested by Proparco, a

French Development Financing Institution for

USD 12.5 Mn valuing African operation at

USD 60Mn)

100% stake

Africa and India BrandsRegional Sales exceeding USD 39Mn

21

22

USD Million

H113 vs H112 - Actuals2013 Guidance

USD 36

Mn

USD 182 Mn

Consolidated Revenue

Consolidated EBITDA

Financial Snapshot - Pharma BusinessPerformance ahead of Guidance

75

84

H1'12 H1'13

Revenue

10

18

H1'12 H1'13

EBITDA

Group Overview

Strides Global Organization

Strides Arcolab

Agila Biotech Agila Specialties

9 Global Manufacturing

Assets

Front-end Business

IP led Partnerships

Research & Development

5 Global Manufacturing

AssetsIndia Brands Africa Brands

Wholly Owned Subsidiary

24

Customer focused business organization with dedicated management team

Pharma Business

Wholly Owned Subsidiary

Key Performance IndicatorsRobust Performance across

Revenue from operations

Profit after tax

Operational EBITDA

Margins trend

25

EPS

USD Million

29

74

77

105

11

14

20

0

39 60

97

105

2009 2010 2011 2012

172 222 326

427 76 108

155 8

248

329

481 436

2009 2010 2011 2012

40.05 40.23

57.74 58.08 58.80

0.50 0.49 0.49 0.72

2.69

-

0.50

1.00

1.50

2.00

2.50

3.00

2008 2009 2010 2011 2012

-

10.00

20.00

30.00

40.00

50.00

60.00

70.00

Outstanding Shares EPS

Divested Ascent Operations Group Excluding Divested Ascent Operations

Note: CAGR excluding divested Ascent operations

*Includes Profit on sale of Ascent Australasia operations

16%

22%20%

24%

2009 2010 2011 2012

20 23 42

158

2009 2010 2011 2012

USD Million

Strengthened Balance Sheet post Ascent transactionNet Debt/Equity at 0.70 in 2012 vs 1.68 in 2011

26

Governance @ Strides

Six out of Eight Board Members are

Independent and Non-Executive

Strategic themes across the Group are

driven by Global Leadership Committee

(GLC)

Empowered Business Management

team with end to end accountability

Integrated Management Review from

Operations to External Reporting

Annual Report received consecutive

recognitions for disclosure and

presentation of financials.

Eminent Independent Directors

Deepak Vaidya Chairman of the Board

Was Country Head of Schroder Capital Partners (Asia) Pte. Ltd.

M.R Umarji Chairman of the Audit Committee

Was Executive Director at RBI. Presently the Chief Legal Advisor

to the Indian Banks Association

S Sridhar

Was CMD of Central Bank of India, ED & COO of Exim Bank,

CMD of National Housing Bank.

P.M. Thampi

Was Chairman and Managing Director of BASF India

A.K Nair

Was MD of KSIDC. MD of Kerala Chemicals and Proteins Limited

Mukul Sarkar

Exim Bank Nominee. General Manager and Group Head, Exim Bank

Corporate Governance

27

28

Sale of Ascent

Pharma

Sale of Agila

A 700% increase in the

Market Cap over 5

years, significantly

outpacing the BSE

increase of 10% over

the same period

Strides (market share price in USD)

Sensex (indexed to Strides)

Investment Phase

Source: BSE,India.

28

Strides has Delivered High Value Creation to its Shareholders

0

5

10

15

20

25

1-Feb-08 1-Dec-08 1-Oct-09 1-Aug-10 1-Jun-11 1-Apr-12 1-Feb-13

Shareholding Pattern

29

as of 30th June 2013

Thank You

Strides Arcolab LimitedStrides House, Bilekahalli, Bannerghatta RoadBangalore 560076, IndiaTel: +91 80 67840738 / 67840290Fax: +91 80 67840200Web: www.stridesarco.com